Actively Recruiting
Evaluating Safety and Early Effects of CTX112, a CRISPR-Cas9 Engineered CAR T Cell Therapy, in Adults With Relapsed or Refractory Hematologic Autoimmune Diseases
Led by CRISPR Therapeutics AG · Updated on 2026-10-20
60
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and early effects of CTX112, also called Zugocabtagene geleucel or zugo-cel, in adults who have relapsed or refractory hematologic autoimmune diseases such as primary Immune Thrombocytopenia ITP and primary Warm Autoimmune Hemolytic Anemia wAIHA. These diseases involve autoantibodies attacking blood cells, causing serious health problems and reduced quality of life. Current treatments may fail for some patients, highlighting the need for new options. This trial is a Phase 12, single-group, open-label study conducted at multiple centers. Participants will receive CTX112, an allogeneic CD19-directed CAR T cell therapy made from healthy donor T cells modified with CRISPR-Cas9 technology. The treatment is given as an intravenous infusion following lymphodepleting chemotherapy. This off-the-shelf therapy is being studied for its safety and potential clinical responses after a single administration. Up to 60 participants may enroll, and the total study duration can last up to five years. During the trial, participants will undergo scheduled visits and laboratory tests to monitor safety and treatment effects. Researchers will evaluate safety outcomes within 28 days after infusion and assess pharmacodynamics, pharmacokinetics, and preliminary efficacy for up to 60 months post-infusion. Participants must comply with contraception guidelines and other trial procedures throughout the study. The long-term follow-up aims to gather comprehensive data on CTX112s impact in this patient population.
CONDITIONS
Brief Title
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Research Team
C
Clinical Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here